- page 8

Alpha Cancer Technologies Inc.
to an embryonic state, with up to 80% of solid
and liquid tumors expressing AFP receptors. By
attaching a chemotherapy “payload” to AFP, the
company can selectively deliver toxins to can-
cer cells because AFP can only enter the cells
expressing AFP receptors and mature healthy
cells do not have this receptor. This targeted
delivery prevents chemotherapy from entering
normal cells, which increases its effectiveness
and significantly reduces toxicity.
“If you load AFP with chemotherapy instead
of nutrients, it acts as a Trojan horse that enters
the cancer cell, and delivers this chemotherapy
selectively to these cells,” Sherman says.
The company has several promising products
that include non-covalently bound chemo-
therapy, such as paclitaxel, thapsigargin, and
chemically linked chemotherapy, such as may-
tansinoids. These generic chemotherapy drugs
have been proven effective but are associated
with significant toxicity including, bloody diar-
rhea, hair loss, vomiting, nausea and damage
to peripheral nerves. AFP itself has been proven
safe with no significant toxicity seen in over 400
patients in Phase I and II clinical studies. Only
mild irritation at the injection sitewas observed
in these patients. In vitro and in vivo results
show that the company’s lead product ACT-901
Once attached to the receptor AFP enters the cancer cell by a process called endocytosis and
delivers its chemotherapy payload which destroys the cancer cell.
1,2,3,4,5,6,7 9,10,11,12
Powered by FlippingBook